Search

everythinglearnresearchcommunity

for

Search:↓

EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.

The document concludes that adenosine receptor agonists have potential for treating various conditions, but only a few are approved due to challenges like side effects and the need for selective activation.

Targeting NCoR1 can help treat heart enlargement and dysfunction.

The new assay can help develop products for hair re-growth.

Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.

Some drugs linked to growth hormones may increase the chance of hair loss in women.

Certain histamine receptors (H2R, H3R, H4R) have unique roles in treating skin diseases, with H2R helping with chronic urticaria and other conditions, H3R providing pain relief and allergy benefits, and H4R reducing inflammation and itchiness.

A natural steroid in the body may protect against eye damage in glaucoma.

The retinoid receptor antagonist effectively disrupts vitamin A-related development in embryos.

Direct vasodilators and sympatholytic agents are still useful for certain conditions despite being less common due to side effects and newer drugs.

Hydralazine and minoxidil are blood pressure medications that relax blood vessels, with potential side effects like rapid heartbeat and fluid retention, and are used for severe or pregnancy-related hypertension.

Some drugs can cause serious side effects, like hypoglycemia from mix-ups, skin reactions, or depression, and while penicillamine may help rheumatoid arthritis more than auranofin, it has more severe side effects.

PTHRP agonists can stimulate hair growth, especially in damaged follicles, while antagonists may initially increase growth but ultimately inhibit it.

Diagnosing and managing Glucocorticoid Resistance Syndrome is complex due to genetic differences and varied symptoms.

Allopregnanolone is needed for certain brain processing issues caused by D1 dopamine receptor activation.

dAR-6–1 is a promising new treatment for hair loss that works better than minoxidil.

Some skin medications can have harmful interactions with the COVID-19 drug nirmatrelvir-ritonavir, but not with molnupiravir.

Rimegepant causes more nausea and skin issues, while ubrogepant causes more muscle issues; personalized treatment is important.

3α‐OH‐DHP is essential for reducing nerve activity related to blood pressure control during pregnancy.

HNG helps hair grow by keeping hair in the growth phase longer.

GLP-1 RAs help with diabetes and skin issues but can cause skin reactions and surgery challenges.

New nonsteroidal molecules can potentially increase dihydrotestosterone in neurons by blocking certain enzymes, without affecting prostate and seminal vesicle weight.

Growth hormone may protect skin from radiation damage.

Using existing drugs for new purposes could be a cost-effective way to treat chest pain and non-clogged heart arteries, with some drugs for lung blood pressure showing promise but needing more testing.

Nirogacestat can cause severe skin issues like hidradenitis suppurativa.

GLP-1RA therapy may increase the risk of hair loss.

Blocking a protein called prostaglandin D2 might help treat hair loss.

AHR ligands could treat inflammatory skin diseases.

Blocking a specific receptor slows down hair loss in mice.

Genetic defects in the glucocorticoid receptor gene can cause conditions with abnormal sensitivity to stress hormones, and other factors may also affect this sensitivity.